Genomic data on cancer treatment released to public

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Johnathan Dwyer)
(Image: Getty/Johnathan Dwyer)

Related tags: Genomics, Sanger Institute, Lilly, Merck

New data on the genetic biomarkers impacting the development of cancer treatments has been released creating the largest publicly accessible dataset of its kind.

The data comes from the Genomics of Drug Sensitivity in Cancer project, which is funded by the Wellcome Sanger Institute, which has created an open-access data website​ for researchers and companies to utilize.

Sanger’s database contains information related to 453 cancer treatment compounds, 989 cancer cell lines, 494,973 genomic associations and 386,293 drug dose response curves. Accumulating the data took researchers four years and doubled the amount of data available from previous iterations of the study.

The project has been ongoing for 10 years aiming to provide freely available data for researchers to discover new therapeutic options by identifying biomarkers responsible for certain cancer treatments being more effective in certain individuals than others.

The data itself is gathered through combining hospital patients’ cancer cell lines with licensed and experimental cancer drugs from pharma companies. The patients’ reaction is then gathered at the genomic level to determine how a person’s DNA affects response to treatment.

“Our Genomics of Drug Sensitivity in Cancer database is the world’s largest repository for information on how a cancer’s underlying genomic landscape influences its response to cancer treatments. We hope it will provide new insights that will point to new ways to target, and treat individual tumors,”​ Mathew Garnett, co-lead of the Genomics of Drug Sensitivity in Cancer project, and group leader at the Wellcome Sanger Institute.

This line of inquiry to develop new pharmaceutical treatments has been on the rise in recent years, with gene therapies and approvals based on biomarkers on the rise.

Eli Lilly began the year with an $8bn (€7.18bn) acquisition of Loxo Oncology​, a biotech which focuses on developing treatments for patients with single abnormalities. While fellow pharma giant, GSK has also seen the potential in focusing on genomics​ to allow for more targeted drug development.

Merck, known as MSD in North America, also gained the first approval for a biomarker-based indication​ for its treatment, Keytruda (pembrolizumab).

The Genomics of Drug Sensitivity in Cancer project has already seen success with its approach, with drug trials into PARP inhibitors​ instigated through the research carried out by the project – eventually leading to 70 research studies into the area.

Related news

Show more

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more